These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18532997)

  • 1. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.
    Umemura K; Furuta T; Kondo K
    J Thromb Haemost; 2008 Aug; 6(8):1439-41. PubMed ID: 18532997
    [No Abstract]   [Full Text] [Related]  

  • 2. The CYP2C19*17 variant is not independently associated with clopidogrel response.
    Lewis JP; Stephens SH; Horenstein RB; O'Connell JR; Ryan K; Peer CJ; Figg WD; Spencer SD; Pacanowski MA; Mitchell BD; Shuldiner AR
    J Thromb Haemost; 2013 Sep; 11(9):1640-6. PubMed ID: 23809542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.
    Danielak D; Karaźniewicz-Łada M; Wiśniewska K; Bergus P; Burchardt P; Komosa A; Główka F
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):99-107. PubMed ID: 26891871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
    Perry CG; Shuldiner AR
    J Hum Genet; 2013 Jun; 58(6):339-45. PubMed ID: 23697979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.
    Backman JD; O'Connell JR; Tanner K; Peer CJ; Figg WD; Spencer SD; Mitchell BD; Shuldiner AR; Yerges-Armstrong LM; Horenstein RB; Lewis JP
    Pharmacogenet Genomics; 2017 Apr; 27(4):159-163. PubMed ID: 28207573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.
    Danielak D; Karaźniewicz-Łada M; Komosa A; Burchardt P; Lesiak M; Kruszyna Ł; Graczyk-Szuster A; Główka F
    Eur J Clin Pharmacol; 2017 Dec; 73(12):1623-1632. PubMed ID: 28914344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
    Scott SA; Sangkuhl K; Stein CM; Hulot JS; Mega JL; Roden DM; Klein TE; Sabatine MS; Johnson JA; Shuldiner AR;
    Clin Pharmacol Ther; 2013 Sep; 94(3):317-23. PubMed ID: 23698643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
    Holmes MV; Perel P; Shah T; Hingorani AD; Casas JP
    JAMA; 2011 Dec; 306(24):2704-14. PubMed ID: 22203539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
    Paré G; Mehta SR; Yusuf S; Anand SS; Connolly SJ; Hirsh J; Simonsen K; Bhatt DL; Fox KA; Eikelboom JW
    N Engl J Med; 2010 Oct; 363(18):1704-14. PubMed ID: 20979470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
    Sibbing D; Stegherr J; Latz W; Koch W; Mehilli J; Dörrler K; Morath T; Schömig A; Kastrati A; von Beckerath N
    Eur Heart J; 2009 Apr; 30(8):916-22. PubMed ID: 19193675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis Pharmacogenomics: A Path to Personalized Medicine.
    Babayeva M; Loewy ZG
    Curr Issues Mol Biol; 2023 Apr; 45(4):3479-3514. PubMed ID: 37185752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics Informs Cardiovascular Pharmacotherapy.
    Babayeva M; Azzi B; Loewy ZG
    Methods Mol Biol; 2022; 2547():201-240. PubMed ID: 36068466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of Antiplatelet Therapy.
    Castrichini M; Luzum JA; Pereira N
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():211-229. PubMed ID: 35914768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for adverse drug reactions associated with clopidogrel therapy.
    Mugosa S; Radosavljevic I; Sahman M; Djordjevic N; Todorovic Z
    Open Med (Wars); 2022; 17(1):694-701. PubMed ID: 35480401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics to guide cardiovascular drug therapy.
    Duarte JD; Cavallari LH
    Nat Rev Cardiol; 2021 Sep; 18(9):649-665. PubMed ID: 33953382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.